Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Socazolimab (ZKAB001), an anti-PD-L1 monoclonal antibody, demonstrates enduring safety and efficacy in treating recurrent or metastatic cervical cancer. Additionally, it shows promise for treating small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma, and osteosarcoma [1] [2] [3] [4] [5].
説明 | Socazolimab (ZKAB001), an anti-PD-L1 monoclonal antibody, demonstrates enduring safety and efficacy in treating recurrent or metastatic cervical cancer. Additionally, it shows promise for treating small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma, and osteosarcoma [1] [2] [3] [4] [5]. |
分子量 | N/A |
CAS No. | 2305043-30-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Socazolimab 2305043-30-3 Inhibitor inhibitor inhibit